Induction of BCL2-interacting killer, BIK, is mediated for anti-cancer activity of curcumin in human head and neck squamous cell carcinoma cells

Journal of Cancer

Volumn 6, Issue 4, 2015, Pages 327-332

  Xi, Yue ^a,b   Gao, Hang ^a   Callaghan, Michael U ^b   Fribley, Andrew M ^b,c   Garshott, Danielle M ^b   Xu, Zhi Xiang ^a,d   Zeng, Qinghua ^a,d   Li, Yu Lin ^a  

^a Basic Medical College   (China)

^b WAYNE STATE UNIVERSITY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 INTERACTING KILLER PROTEIN; BIM PROTEIN; CASPASE 3; CASPASE 9; CURCUMIN; CYTOCHROME C; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IC50; IMMUNOBLOTTING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA CELL; UPREGULATION;

EID: 84923776680     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.11185     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA: a cancer journal for clinicians. 2007; 57: 43-66.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians. 2005; 55: 74-108.
3. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer research. 2009; 69: 1958-65.
4. Boehm AL, Sen M, Seethala R, Gooding WE, Freilino M, Wong SM, et al. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Molecular pharmacology. 2008; 73: 1632-42.
5. Sorenson CM, Eastman A. Mechanism of cis-diamminedichloroplatinum(II)- induced cytotoxicity: role of G2 arrest and DNA double-strand breaks. Cancer research. 1988; 48: 4484-8.
6. Matta A, Ralhan R. Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head & neck oncology. 2009; 1: 6.
7. Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology. Nature reviews Clinical oncology. 2009; 6: 266-77.
8. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15: 3740-50.
9. Amit I, Wides R, Yarden Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Molecular systems biology. 2007; 3: 151.
10. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Seminars in oncology. 2006; 33: 407-20.
11. Zhang YJ, Tian XQ, Sun DF, Zhao SL, Xiong H, Fang JY. Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer. Cancer investigation. 2009; 27: 273-85.
12. Adjei AA. Targeting multiple signal transduction pathways in lung cancer. Clinical lung cancer. 2005; 7 Suppl 1: S39-44.
13. Adjei AA, Hidalgo M. Treating cancer by blocking cell signals. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23: 5279-80.
14. Adjei AA, Hidalgo M. Intracellular signal transduction pathway proteins as targets for cancer therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005; 23: 5386-403.
15. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? The AAPS journal. 2009; 11: 495-510.
16. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochemical pharmacology. 2006; 71: 1397-421.
17. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K, Dannenberg AJ. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 1999; 20: 445-51.
18. Chen H, Zhang ZS, Zhang YL, Zhou DY. Curcumin inhibits cell proliferation by interfering with the cell cycle and inducing apoptosis in colon carcinoma cells. Anticancer research. 1999; 19: 3675-80.
19. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Molecular and cellular biology. 2004; 24: 9695-704.
20. Fribley AM, Miller JR, Brownell AL, Garshott DM, Zeng Q, Reist TE, et al. Celastrol induces unfolded protein response-dependent cell death in head and neck cancer. Experimental cell research. 2014.
21. Zeng Q, Chen S, You Z, Yang F, Carey TE, Saims D, et al. Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa B. The Journal of biological chemistry. 2002; 277: 25203-8.
22. Bossy-Wetzel E, Green DR. Caspases induce cytochrome c release from mitochondria by activating cytosolic factors. The Journal of biological chemistry. 1999; 274: 17484-90.
23. Shehzad A, Lee YS. Molecular mechanisms of curcumin action: signal transduction. BioFactors. 2013; 39: 27-36.
24. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Molecular cancer. 2011; 10: 12.
25. Zeng Q, McCauley LK, Wang CY. Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. The Journal of biological chemistry. 2002; 277: 50137-42.
26. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer cell. 2005; 8: 13-23.
27. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer metastasis reviews. 2010; 29: 405-34.
28. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. Journal of natural products. 2003; 66: 1022-37.
29. Zhu S, Moore TW, Morii N, Howard RB, Arrendale RF, Reddy P, et al. Synthetic curcumin analog UBS109 inhibits the growth of head and neck squamous cell carcinoma xenografts. Current cancer drug targets. 2014; 14: 380-93.
30. Kumar B, Yadav A, Hideg K, Kuppusamy P, Teknos TN, Kumar P. A novel curcumin analog (H-4073) enhances the therapeutic efficacy of cisplatin treatment in head and neck cancer. PLoS One. 2014; 9: e93208.
31. Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, et al. The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies. Oncotarget. 2014.
32. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116: 205-19.
33. Tait SW, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nature reviews Molecular cell biology. 2010; 11: 621-32.
34. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene. 1995; 11: 1921-8.
35. Rashmi R, Pillai SG, Vijayalingam S, Ryerse J, Chinnadurai G. BH3-only protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null cells. Oncogene. 2008; 27: 1366-75.
36. Fribley AM, Miller JR, Reist TE, Callaghan MU, Kaufman RJ. Large-scale analysis of UPR-mediated apoptosis in human cells. Methods in enzymology. 2011; 491: 57-71.
37. Nikitakis NG, Scheper MA, Papanikolaou VS, Sauk JJ. The oncogenic effects of constitutive Stat3 signaling in salivary gland cancer cells are mediated by survivin and modulated by the NSAID sulindac. Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics. 2009; 107: 826-36.
38. Liu B, Ren Z, Shi Y, Guan C, Pan Z, Zong Z. Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. The Laryngoscope. 2008; 118: 1976-80.
39. Nagpal JK, Mishra R, Das BR. Activation of Stat-3 as one of the early events in tobacco chewing-mediated oral carcinogenesis. Cancer. 2002; 94: 2393-400.
40. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000; 19: 2489-95.
41. Kupferman ME, Jayakumar A, Zhou G, Xie T, Dakak-Yazici Y, Zhao M, et al. Therapeutic suppression of constitutive and inducible JAK\STAT activation in head and neck squamous cell carcinoma. Journal of experimental therapeutics & oncology. 2009; 8: 117-27.
42. Leeman-Neill RJ, Wheeler SE, Singh SV, Thomas SM, Seethala RR, Neill DB, et al. Guggulsterone enhances head and neck cancer therapies via inhibition of signal transducer and activator of transcription-3. Carcinogenesis. 2009; 30: 1848-56.
43. Prakobwong S, Gupta SC, Kim JH, Sung B, Pinlaor P, Hiraku Y, et al. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis. 2011; 32: 1372-80.
44. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS, Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 1998; 281: 1680-3.
45. Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996; 274: 782-4.
46. Rubin Grandis J, Zeng Q, Drenning SD. Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer. The Laryngoscope. 2000; 110: 868-74.
47. Siavash H, Nikitakis NG, Sauk JJ. Abrogation of IL-6-mediated JAK signalling by the cyclopentenone prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells. British journal of cancer. 2004; 91: 1074-80.
48. Dassonville O, Bozec A, Fischel JL, Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Critical reviews in oncology/hematology. 2007; 62: 53-61.
49. Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11: 8105-8.
50. Cooper JB, Cohen EE. Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head & neck. 2009; 31: 1086-94.